{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:36:38Z","timestamp":1790940998182,"version":"4.1.0"},"reference-count":17,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,12,8]],"date-time":"2008-12-08T00:00:00Z","timestamp":1228694400000},"content-version":"vor","delay-in-days":37,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Influenza Resp Viruses"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold>Our studies aimed to evaluate in clinical trials the safety and immunogenicity of an H5 live influenza vaccine candidate obtained using classical reassortment techniques from a low pathogenicity avian influenza (LPAI) A\/Duck\/Potsdam\/1402\u20106\/86(H5N2) virus and the cold\u2010adapted (<jats:italic>ca<\/jats:italic>) donor strain A\/Leningrad\/134\/17\/57(H2N2).<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold>During Phase I\u2013II clinical trials, volunteers received intranasally two doses of reassortant influenza vaccine strain A\/17\/Duck\/Potsdam\/86\/92 (H5N2) 21\u2003days apart. Clinical examination of all vaccinees was conducted 7\u2003days post\u2010vaccination. Serum antibody responses were measured by hemagglutination\u2010inhibition and microneutralization and local antibodies were estimated using an enzyme\u2010linked immunosorbent assay test.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold>The vaccine was safe and of low reactogenicity with no febrile reactions. After revaccination 47\u00b71\u201354\u00b78% of subjects showed \u2265fourfold seroconversions of Hamagglutination inhibition (HAI) antibodies to the hemagglutinin (HA) antigen of the A\/17\/Duck\/Potsdam\/86\/92 (H5N2) virus and 29\u00b74\u201330\u00b78% were seroconverted to the HA antigen of the reverse genetics reassortant A\/Indonesia\/05\/2005\u2003\u00d7\u2003PR8 IBCDC\u2010RG (H5N1). Virus\u2010neutralizing antibody levels in sera of volunteers were similar to those shown in HAI test. The virus\u2010specific nasal IgA antibody response after two vaccine doses demonstrated significant increases of \u2265fourfold rise SIgA antibodies (65%) geometrical mean titers (16\u00b70) and a rise in SIgA antibodies (2\u00b78) compared with one dose.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold>The live attenuated influenza vaccine candidate prepared using the LPAI A(H5N2) strain was well tolerated and elicited serum and local immune responses. There was evident cross\u2010reactivity to the A(H5N1) strain in the HAI test.<\/jats:p>","DOI":"10.1111\/j.1750-2659.2008.00064.x","type":"journal-article","created":{"date-parts":[[2008,12,9]],"date-time":"2008-12-09T22:50:35Z","timestamp":1228863035000},"page":"203-209","source":"Crossref","is-referenced-by-count":51,"title":["Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I\u2013II clinical trials)"],"prefix":"10.1111","volume":"2","author":[{"given":"Larisa","family":"Rudenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Desheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Korovkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Mironov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Rekstin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Grigorieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Donina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Gambaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Katlinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,12,30]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/168.4.881"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0531-5131(01)00661-6"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.06.023"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.039"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2002.1742"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055778"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030360"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(82)90034-1"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-0934(94)00133-2"},{"key":"e_1_2_6_11_2","first-page":"1107","article-title":"Differences between influenza virus receptors on target cells duck and chicken and receptor specificity of the 1997 H5N1 chicken and human influenza viruses from Hong Kong","volume":"147","author":"Gambaryan AS","year":"2002","journal-title":"Arch Virol"},{"key":"e_1_2_6_12_2","volume-title":"WHO manual on animal influenza diagnosis and surveillance","author":"World Health Organization"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.4.937-943.1999"},{"key":"e_1_2_6_14_2","first-page":"122","volume-title":"Options for the Control of Influenza VI","author":"Rudenko LG","year":"2008"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2004.05.009"},{"key":"e_1_2_6_16_2","volume-title":"Options for live influenza vaccines (LAIV) in the control of epidemic and pandemic influenza, 12\u201013 June 2007","author":"World Health Organization"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7883\/yoken.JJID.2005.195","article-title":"Mechanisms of broad cross\u2010protection provided by Influenza virus infection and their application to vaccines","volume":"58","author":"Tamura S","year":"2005","journal-title":"Jpn J Infect Dis"},{"key":"e_1_2_6_18_2","volume-title":"Global pandemic influenza action plan to increase vaccine supply","author":"World Health Organization"}],"container-title":["Influenza and Other Respiratory Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1750-2659.2008.00064.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1750-2659.2008.00064.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1750-2659.2008.00064.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T20:54:39Z","timestamp":1709758479000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1750-2659.2008.00064.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1111\/j.1750-2659.2008.00064.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1750-2659.2008.00064.x","archive":["Portico"],"relation":{},"ISSN":["1750-2640","1750-2659"],"issn-type":[{"value":"1750-2640","type":"print"},{"value":"1750-2659","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}